The new migraine drug ‘Ajovy’ is now being administered without reimbursement in Korea.

According to industry sources, Teva-Handok Pharma’s Calcitonin gene-related peptide (CGRP) targeting migraine drug, Ajovy (fremanezumab), which was released in Korea on the 18th of last month, is now available for prescriptions at several medical institutions, including the Shinchon Severance Hospital.

However, the drug has only passed a few drug committee (DC) reviews at general hospitals yet. Instead, the company had set a pre-order system for the drug for supply due to a flood of inquiries from patients whose symptoms recurred after taking Lilly's Emgality (galcanezumab)', another migraine drug